

Biology

LLUCC-BIOSPECIMEN
LABORATORY - SPECIMEN
COLLECTION

Loma Linda University Cancer Center Biospecimen Laboratory Specimen Collection
Protocol

[C.S. Chen, M.D. PhD](#)

Breast

NOVARTIS-CRAD001J2101

A phase Ib/II study investigating the combination of RAD001 with trastuzumab and paclitaxel in patients with HER2-positive metastatic breast cancer
<http://clinicaltrials.gov/ct2/show/NCT00426556?term=CRAD001J2101&rank=1>

[Hamid Mirshahidi, M.D.](#)

NSABP-B40

A Randomized Phase III Trial of Neoadjuvant Therapy in Patients with Palpable and Operable Breast Cancer Evaluating the Effect on Pathologic Complete Response (pCR) of Adding Capecitabine or Gemcitabine to Docetaxel when Administered Before AC with or without Bevacizumab and Correlative Science Studies Attempting to Identify Predictors of High Likelihood for pCR with Each of the Regimens
<http://clinicaltrials.gov/ct2/show/NCT00408408?term=NSABP-B40&rank=1>

[Thomas Godfrey, M.D.](#)

NSABP-B42

A Clinical Trial to Determine the Efficacy of Five Years of Letrozole Compared to Placebo in Patients Completing Five Years of Hormonal Therapy Consisting of an Aromatase Inhibitor (AI) or Tamoxifen Followed by an AI in Prolonging Disease-Free Survival in Postmenopausal Women with Hormone Receptor Positive Cancer
<http://clinicaltrials.gov/ct2/show/NCT00382070?term=NSABP-B42&rank=1>

[Thomas Godfrey, M.D.](#)

SWOG-N063D ALTTO

Adjuvant Lapatinib and/or Trastuzumab Treatment Optimisation Study A randomised, multi-centre, open-label, phase III study of adjuvant lapatinib, trastuzumab, their sequence and their combination in patients with HER2/ErbB2 positive primary breast cancer Adjuvant Lapatinib and/or Trastuzumab Treatment Optimisation Study
<http://clinicaltrials.gov/ct2/show/NCT00490139?term=N063D&rank=1>

[Thomas Godfrey, M.D.](#)

SWOG-S0500

A Randomized Phase III Trial to Test the Strategy of Changing Therapy Versus Maintaining Therapy for Metastatic Breast Cancer Patients who Have Elevated Circulating Tumor Cell Levels at First Follow-Up Assessment
<http://clinicaltrials.gov/ct2/show/NCT00382018?term=S0500&rank=1>

[Thomas Godfrey, M.D.](#)

SWOG-TAILORX

ECOG-Program of the assessment of clinical tests(PACCT-1): Trial assigning individualized options for treatment: the TAILORx trial
<http://clinicaltrials.gov/ct2/show/NCT00310180?term=TAILORX&rank=1>

[Thomas Godfrey, M.D.](#)

Endocrine

NOVARTIS-CSOM230C2303

A multicenter, randomized, blinded efficacy and safety study of pasireotide LAR vs octreotide LAR in patients with metastatic carcinoid tumors whose disease-related symptoms are inadequately controlled by somatostatin analogues
<http://clinicaltrials.gov/ct2/show/NCT00690430?term=CSOM230C2303&rank=1>

[Chung-Tsen Hsueh, M.D. PhD](#)

GI

ACOSOG-Z5041

A Phase II Study of Preoperative Gemcitabine and Erlotinib Plus Pancreatectomy and Postoperative Gemcitabine and Erlotinib for Patients with Operable Pancreatic Adenocarcinoma
<http://clinicaltrials.gov/ct2/show/NCT00733746?term=ACOSOG-Z5041&rank=1>

[Mark Reeves, M.D., PhD](#)

GLAXO-LPT109747

An exploratory, phase II trial to determine the association of lapatinib induced fluoropyrimidine gene changes with efficacy parameters of lapatinib and capecitabine in first line gastric cancer
<http://clinicaltrials.gov/ct2/show/NCT00526669?term=LPT109747&rank=1>

[Chung-Tsen Hsueh, M.D. PhD](#)

NSABP-R-04

a clinical trial comparing preoperative radiation therapy and capecitabine with or without oxaliplatin with preoperative radiation therapy and continuous intravenous infusion of 5-fluorouracil with or without oxaliplatin in the treatment of patients with operable carcinoma of the rectum
<http://clinicaltrials.gov/ct2/show/NCT00058474?term=NSABP-R-04&rank=1>

[Chung-Tsen Hsueh, M.D. PhD](#)

SWOG-E5202

A Randomized Phase III Study comparing 5-FU, Leucovorin and Oxaliplatin versus 5-FU, Leucovorin, Oxaliplatin and Bevacizumab in Patients with Stage II Colon Cancer at High Risk for Recurrence to Determine Prospectively and Prognostic Value of Molecular Markers

[Chung-Tsen Hsueh, M.D. PhD](#)

SWOG-N0147

A Randomized Phase III Trial of Oxaliplatin (OXAL) Plus 5-Fluorouracil (5-FU)/Leucovorin (CF) with or without Cetuximab (C225) after Curative Resection for Patients with Stage III Colon Cancer
<http://clinicaltrials.gov/ct2/show/NCT00079274?term=N0147&rank=1>

[Chung-Tsen Hsueh, M.D. PhD](#)

SWOG-S0600

Phase III Trial of Irinotecan-Based Chemotherapy Plus Cetuximab (NSC-714692) with or without Bevacizumab (NSC-704865) as Second-Line Therapy for Patients with Metastatic Colorectal Cancer who have Progressed on Bevacizumab with Either FOLFOX, OPTIMOX or XELOX
<http://clinicaltrials.gov/ct2/show/NCT00499369?term=S0600&rank=1>

[Chung-Tsen Hsueh, M.D. PhD](#)

GU

MILLEN.-03-1218

VELCADE® (bortezomib) for Injection therapy for early relapsed prostate cancer

[C.S. Chen, M.D. PhD](#)

<http://clinicaltrials.gov/ct2/show/NCT00103376?term=VELCADE%C2%AE+%28bortezomib%29+for+Injection+therapy+for+early+relapsed+prostate+cancer&rank=1>

A Phase II Trial of Dasatinib (Sprycel®) in Subjects with Hormone-refractory Prostate Cancer, Previously Treated with Chemotherapy

[C.S. Chen, M.D. PhD](#)

<http://clinicaltrials.gov/ct2/show/NCT00570700?term=Dasatinib+%28Sprycel%29+in+Subjects+with+Hormone-refractory+Prostate&rank=1>

H&N

GENMAB-GEN205

An Open label single arm trial investigating zalutumumab, a Human Monoclonal Anti-EGF receptor Antibody, in combination with Best Supportive Care, in Patients with Non-Curable Squamous Cell Carcinoma of the Head and Neck who have Failed Standard Platinum-based Chemotherapy

[Chung-Tsen Hsueh, M.D. PhD](#)

<http://clinicaltrials.gov/ct2/show/NCT00542308?term=Head+and+Neck+%2B+Genmab&rank=2>

Leukemia

NOVARTIS-CAMN107AUS09

A multi-center, open-label, exploratory study of Bcr-Abl kinetics in adult patients on nilotinib with Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia in chronic phase (CML-CP) and a suboptimal molecular response to imatinib

[C.S. Chen, M.D. PhD](#)

<http://clinicaltrials.gov/ct2/show/NCT00644878?term=CAMN107AUS09&rank=1>

Lung

APTIVM-05LUN01

A Phase I/II Clinical Trial of Bortezomib (Velcade) + Pemetrexed (Alimta) in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer

[Hamid Mirshahidi, M.D.](#)

<http://clinicaltrials.gov/ct2/show/NCT00516100?term=05LUN01&rank=1>

NOVARTIS-CASA404A2301

A Phase III, randomized, double-blind, placebo-controlled multi-center study of ASA404 in combination with paclitaxel and carboplatin as first-line treatment for locally advanced or metastatic (stage IIIb/IV) non-small cell lung cancer (NSCLC)(ATTRACT 1)

[Hamid Mirshahidi, M.D.](#)

<http://clinicaltrials.gov/ct2/show/NCT00662597?term=CASA404A2301&rank=1>

OSI-OSI-774-302

A Multi-center, Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Single-agent Tarceva® (erlotinib) Following Complete Tumor Resection with or without Adjuvant Chemotherapy in Patients with Stage IB-III A Non small Cell Lung Carcinoma who have EGFR-positive Tumors (RADIANT)

[Hamid Mirshahidi, M.D.](#)

<http://clinicaltrials.gov/ct2/show/NCT00373425?term=774-302&rank=1>

PFIZER-A4021016 Randomized, Open Label, Phase III Trial of CP-751,871 in Combination with Paclitaxel and Carboplatin versus Paclitaxel and Carboplatin in Patients with Non-Small Cell Lung Cancer
<http://clinicaltrials.gov/ct2/show/NCT00596830?term=A4021016&rank=1> [Hamid Mirshahidi, M.D.](#)

SANOFI-AVENTIS-EFC10261 A Multinational, Randomized, Double-Blind Study Comparing Aflibercept Versus Placebo in Patients Treated with Second-Line Docetaxel after Failure of One Platinum Based Therapy for Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC)
<http://clinicaltrials.gov/ct2/show/NCT00532155?term=EFC10261&rank=1> [Hamid Mirshahidi, M.D.](#)

Lymphoma

CELGENE-CC-5013-MCL-001 A Phase II Multicenter, single-arm, open-label study to determine the efficacy and safety of single-agent, lenalidomide (Revlimid®) in patients with Mantle Cell Non-Hodgkin's Lymphoma who have relapsed or progressed after treatment with Bortezomib or are refractory to bortezomib (Protocol CC-5013-MCL-001).The "EMERGE" trial.
<http://clinicaltrials.gov/ct2/show/NCT00737529?term=mantle+cell+non+hodgkins+%2B+celgene&rank=4> [C.S. Chen, M.D. PhD](#)

MILLEN.-C05012 A Two-Arm, Non-Randomized, Multicenter, Phase 2 Study of VELCADE® (bortezomib) in Combination with Rituximab, Cyclophosphamide, and Prednisone with or without Doxorubicin followed by Rituximab Maintenance in Subjects with Relapsed Follicular Lymphoma
<http://clinicaltrials.gov/ct2/show/NCT00715208?term=C05012&rank=1> [C.S. Chen, M.D. PhD](#)

Melanoma

SWOG-E1697 Phase III Randomized Study of Four Weeks High Dose IFN-±2b in Stage T2b No, T3a-b, T4a-b No, and T1-4, N1a, 2a (microscopic) Melanoma.
<http://clinicaltrials.gov/ct2/show/NCT00447356?term=E1697&rank=2> [Walter Quan, M.D.](#)

SWOG-S0438 A Randomized Phase II Trial of BAY 43-9006 (Sorafenib; NSC- 724772)with Either CCI-779 (Temsirrolimus; NSC-683864)or R115777 (Tipifarnib; NSC-702818) in Metastatic Melanoma.
<http://clinicaltrials.gov/ct2/show/NCT00281957?term=S0438&rank=1> [Walter Quan, M.D.](#)

Mult. Myeloma

GLOUCESTER-GPI-08-0006

A Phase II Trial of Romidepsin and Bortezomib for Multiple Myeloma Patients with Relapsed or Refractory Disease

[C.S. Chen, M.D. PhD](#)

<http://clinicaltrials.gov/ct2/show/NCT00765102?term=08-0006&rank=1>

ONCOTHERAPEUTIC-X05727/DOXIL
MMY2010

A Phase II Study of Pegylated Liposomal Doxorubicin, Bortezomib and Dexamethasone (DVD) for Patients with Newly Diagnosed Multiple Myeloma (MM)

[C.S. Chen, M.D. PhD](#)

<http://clinicaltrials.gov/ct2/show/NCT00742404?term=doxorubicin%2C+Bortezomib+and+Dexamethasone%09%28DVD%29+for+Patients+with+Newly+Diagnosed+Multiple+Myeloma&rank=1>

Multiple

INV INT-HSUEH - AZACITIDINE

A Phase I Study of Azacitidine in Combination with Cisplatin in Patients with Recurrent or Metastatic Non-small Cell Lung Cancer or Squamous Cell Carcinoma of the Head and Neck

[Chung-Tsen Hsueh, M.D. PhD](#)

<http://clinicaltrials.gov/ct2/show/NCT00901537?term=AZACITIDINE&rank=3>

Renal

SWOG-E2805

Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma

[Walter Quan, M.D.](#)

<http://clinicaltrials.gov/ct2/show/NCT00326898?term=E2805&rank=1>